IDEAYA Biosciences Receives FDA Clearance for First-in-Class Bispecific ADC IDE034 Targeting Multiple Solid Tumors
Key Insights
IDEAYA Biosciences received FDA IND clearance for IDE034, a potential first-in-class bispecific B7H3 (search)/PTK7 (search) TOP1 (search) antibody-drug conjugate targeting multiple solid tumor types.
The therapy targets B7H3 (search)/PTK7 (search) co-expression found in approximately 30% of lung cancers, 46% of colorectal cancers, and 27% of head and neck cancers.
Preclinical studies demonstrated deep and durable tumor regressions with IDE034 monotherapy and enhanced durability when combined with PARG (search) inhibitor IDE161.
IDEAYA Biosciences announced FDA clearance of an investigational new drug (IND) application for IDE034, a potential first-in-class bispecific B7H3 (search)/PTK7 (search) TOP1 (search) antibody-drug conjugate (ADC) designed to treat multiple solid tumor types. The precision medicine oncology company expects to begin enrolling patients in a Phase 1 clinical trial in Q1 2026.
Targeting Co-Expressed Tumor Antigens
IDE034 represents a novel approach to cancer treatment by simultaneously targeting two antigens, B7H3 (search) and PTK7 (search), which are co-expressed across multiple solid tumor types. According to data from the Human Protein Atlas database, B7H3/PTK7 co-expression occurs in approximately 30% of lung cancers, 46% of colorectal cancers, and 27% of head and neck cancers.
"IDE034 has demonstrated robust antitumor activity and selective targeting of B7H3 (search)- and PTK7 (search)-expressing solid tumor models," said Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences. "The high prevalence of B7H3/PTK7 co-expression in solid tumors such as lung, colorectal, and head and neck cancers underscores its broad indication potential."
Promising Preclinical Results
Preclinical studies demonstrated strong anti-tumor activity in B7H3 (search)/PTK7 (search)-positive tumor models, with IDE034 monotherapy producing deep and durable tumor regressions across multiple in-vivo models. The studies support the advancement of IDE034 into clinical development based on its selective targeting capabilities and robust antitumor activity.
Combination Strategy with PARG Inhibition
The company's strategy extends beyond monotherapy to include combination approaches. Enhanced durability was observed when IDE034 was combined with IDE161, IDEAYA's PARG (search) inhibitor, in preclinical in vivo models. This combination approach leverages the mechanistic rationale that TOP1 (search) inhibition induces replication stress and DNA damage, potentially increasing tumor cell reliance on the PARG pathway.
"We are excited to advance our differentiated clinical strategy with now three potentially first-in-class clinical-stage programs focused on enhancing the efficacy of TOP1 (search) ADCs through the PARG (search) DDR combination mechanism," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences. "We believe this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies."
Clinical Development Timeline
The Phase 1 trial will initially evaluate patients with solid tumors known to express B7H3 (search) and PTK7 (search), including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDEAYA plans to share additional preclinical data supporting the mechanistic rationale for the PARG (search) and TOP1 (search) ADC combination at a major medical conference in the first half of 2026.
"IND clearance for IDE034 is an important step in expanding our potential first-in-class TOP1 (search) ADC clinical pipeline into bispecific, precision-guided approaches," Beaupre noted, highlighting the company's broader strategy of developing targeted therapeutics aligned to genetic drivers of disease.